The Potential Role of Innate Immunity in the Pathogenesis of Hodgkin's Lymphoma

Hematology/Oncology Clinics of North America

Volumn 21, Issue 5, 2007, Pages 805-823

  Enblad, Gunilla ^a   Molin, Daniel ^a   Glimelius, Ingrid ^a   Fischer, Marie ^a,b   Nilsson, Gunnar ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; IMMUNOGLOBULIN E; INTERLEUKIN 8; INTERLEUKIN 9; INTERLEUKIN 9 RECEPTOR; LIGAND; VASCULOTROPIN;

ALLERGY; ANGIOGENESIS; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CANCER RISK; CELL ACTIVATION; CELL FUNCTION; CELL INFILTRATION; CELL INTERACTION; CELL TYPE; CELLULAR DISTRIBUTION; CYTOKINE PRODUCTION; CYTOLOGY; DENDRITIC CELL; EOSINOPHIL; EOSINOPHILIA; HEMATOPOIETIC STEM CELL; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; LEUKOCYTE COUNT; MACROPHAGE; MAST CELL; METASTASIS; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REED STERNBERG CELL; REVIEW; T LYMPHOCYTE ACTIVATION; TARGET CELL; TUMOR GROWTH;

EOSINOPHILS; HODGKIN DISEASE; HUMANS; IMMUNITY, NATURAL; LYMPH NODES; MACROPHAGES; MAST CELLS; PARACRINE COMMUNICATION; REED-STERNBERG CELLS;

EID: 34748912429     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.07.007     Document Type: Review

References (98)

1. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70
2. de Visser K.E., Eichten A., and Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6 1 (2006) 24-37
3. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 9255 (2001) 539-545
4. Kuppers R., and Hansmann M.L. The Hodgkin's and Reed/Sternberg cell. Int J Biochem Cell Biol 37 3 (2005) 511-517
5. Pinto A., Gattei V., Zagonel V., et al. Hodgkin's disease: a disorder of dysregulated cellular cross-talk. Biotherapy 10 4 (1998) 309-320
6. Gruss H.J., Pinto A., Duyster J., et al. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol Today 18 4 (1997) 156-163
7. Pinto A., Aldinucci D., Gloghini A., et al. The role of eosinophils in the pathobiology of Hodgkin's disease. Ann Oncol 8 Suppl 2 (1997) 89-96
8. Molin D., Fischer M., Xiang Z., et al. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br J Haematol 114 3 (2001) 616-623
9. Molin D., Edstrom A., Glimelius I., et al. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol 119 1 (2002) 122-124
10. Enblad G., Sundstrom C., and Glimelius B. Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. Hematol Oncol 11 4 (1993) 187-193
11. von Wasielewski R., Seth S., Franklin J., et al. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood 95 4 (2000) 1207-1213
12. Rothenberg M.E., and Hogan S.P. The eosinophil. Annu Rev Immunol 24 (2006) 147-174
13. Venge P., Bystrom J., Carlson M., et al. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy 29 9 (1999) 1172-1186
14. Trulson A., Nilsson S., and Venge P. The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer. Br J Haematol 98 2 (1997) 312-314
15. Peterson C.G., and Venge P. Purification and characterization of a new cationic protein-eosinophil protein-X (EPX)-from granules of human eosinophils. Immunology 50 1 (1983) 19-26
16. Hamid Q., Barkans J., Meng Q., et al. Human eosinophils synthesize and secrete interleukin-6, in vitro. Blood 80 6 (1992) 1496-1501
17. Beil W.J., Weller P.F., Tzizik D.M., et al. Ultrastructural immunogold localization of tumor necrosis factor-alpha to the matrix compartment of eosinophil secondary granules in patients with idiopathic hypereosinophilic syndrome. J Histochem Cytochem 41 11 (1993) 1611-1615
18. Calafat J., Janssen H., Tool A., et al. The bactericidal/permeability-increasing protein (BPI) is present in specific granules of human eosinophils. Blood 91 12 (1998) 4770-4775
19. Levi-Schaffer F., and Weg V.B. Mast cells, eosinophils and fibrosis. Clin Exp Allergy 27 Suppl 1 (1997) 64-70
20. Olsson I., Venge P., Spitznagel J.K., et al. Arginine-rich cationic proteins of human eosinophil granules: comparison of the constituents of eosinophilic and neutrophilic leukocytes. Lab Invest 36 5 (1977) 493-500
21. Peterson C.G., Jornvall H., and Venge P. Purification and characterization of eosinophil cationic protein from normal human eosinophils. Eur J Haematol 40 5 (1988) 415-423
22. Hernnas J., Sarnstrand B., Lindroth P., et al. Eosinophil cationic protein alters proteoglycan metabolism in human lung fibroblast cultures. Eur J Cell Biol 59 2 (1992) 352-363
23. Venge P., Dahl R., and Hallgren R. Enhancement of factor XII dependent reactions by eosinophil cationic protein. Thromb Res 14 4-5 (1979) 641-649
24. Kimata H., Yoshida A., Ishioka C., et al. Inhibition of ongoing immunoglobulin production by eosinophil cationic protein. Clin Immunol Immunopathol 64 1 (1992) 84-88
25. Kimata H., Yoshida A., Ishioka C., et al. Eosinophil cationic protein inhibits immunoglobulin production and proliferation in vitro in human plasma cells. Cell Immunol 141 2 (1992) 422-432
26. Toth J., Dworak O., and Sugar J. Eosinophil predominance in Hodgkin's disease. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 89 1 (1977) 107-111
27. Axdorph U., Porwit-MacDonald A., Grimfors G., et al. Tissue eosinophilia in relation to immunopathological and clinical characteristics in Hodgkin's disease. Leuk Lymphoma 42 5 (2001) 1055-1065
28. Macintyre E.A., Vaughan Hudson B., Vaughan Hudson G., et al. Incidence and clinical importance of bone marrow eosinophilia in Hodgkin's disease (BNLI Report No 29). British National Lymphoma Investigation. J Clin Pathol 40 3 (1987) 245-246
29. Vaughan Hudson B., Linch D.C., Macintyre E.A., et al. Selective peripheral blood eosinophilia associated with survival advantage in Hodgkin's disease (BNLI Report No 31). British National Lymphoma Investigation. J Clin Pathol 40 3 (1987) 247-250
30. Pretlow T.P., Keith E.F., Cryar A.K., et al. Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. Cancer Res 43 6 (1983) 2997-3000
31. Goldsmith M.M., Belchis D.A., Cresson D.H., et al. The importance of the eosinophil in head and neck cancer. Otolaryngol Head Neck Surg 106 1 (1992) 27-33
32. Samoszuk M., and Nansen L. Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. Blood 75 1 (1990) 13-16
33. Glimelius I., Edstrom A., Amini R.M., et al. IL-9 expression contributes to the cellular composition in Hodgkin's lymphoma. Eur J Haematol 76 4 (2006) 278-283
34. Endo M UK, Kitazume K, Iwabe K, et al. Hypereosinophilic syndrome in Hodgkin's disease with increased granulocyte-macrophage colony-stimulating factor. Ann Hematol 1995;71:313-4.
35. Jundt F., Anagnostopoulos I., Bommert K., et al. Hodgkin's/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood 94 6 (1999) 2065-2071
36. Patella V., de Crescenzo G., Marino I., et al. Eosinophil granule proteins activate human heart mast cells. J Immunol 157 3 (1996) 1219-1225
37. Pinto A., Aldinucci D., Gloghini A., et al. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood 88 9 (1996) 3299-3305
38. Kadin M., Butmarc J., Elovic A., et al. Eosinophils are the major source of transforming growth factor-beta 1 in nodular sclerosing Hodgkin's disease. Am J Pathol 142 1 (1993) 11-16
39. Newcom S.R., and Tagra K.K. High molecular weight transforming growth factor beta is excreted in the urine in active nodular sclerosing Hodgkin's disease. Cancer Res 52 24 (1992) 6768-6773
40. Molin D., Glimelius B., Sundstrom C., et al. The serum levels of eosinophil cationic protein (ECP) are related to the infiltration of eosinophils in the tumours of patients with Hodgkin's disease. Leuk Lymphoma 42 3 (2001) 457-465
41. Hasenclever D., and Diehl V. A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's Disease. N Engl J Med 339 21 (1998) 1506-1514
42. Fischer M., Harvima I.T., Carvalho R.F., et al. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Invest 116 10 (2006) 2748-2756
43. Salgami E.V., Efstathiou S.P., Vlachakis V., et al. High pretreatment interleukin-10 is an independent predictor of poor failure-free survival in patients with Hodgkin's lymphoma. Haematologia (Budap) 32 4 (2002) 377-387
44. Axdorph U., Sjoberg J., Grimfors G., et al. Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease. Ann Oncol 11 11 (2000) 1405-1411
45. Bohlen H., Kessler M., Sextro M., et al. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann Hematol 79 3 (2000) 110-113
46. Galli S.J., Nakae S., and Tsai M. Mast cells in the development of adaptive immune response. Nat Immun 6 (2005) 135-142
47. Dimitriadou V., and Koutsilieris M. Mast cell-tumor cell interactions: for or against tumour growth and metastasis?. Anticancer Res 17 3A (1997) 1541-1549
48. Theoharides T.C., and Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 25 5 (2004) 235-241
49. Kirshenbaum A.S., Goff J.P., Semere T., et al. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 94 7 (1999) 2333-2342
50. Galli S.J. Mast cells and basophils. Curr Opin Hematol 7 1 (2000) 32-39
51. Irani A.A., Schechter N.M., Craig S.S., et al. Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci U S A 83 12 (1986) 4464-4468
52. Coussens L.M., Tinkle C.L., Hanahan D., et al. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103 3 (2000) 481-490
53. Ribatti D., Vacca A., Nico B., et al. The role of mast cells in tumour angiogenesis. Br J Haematol 115 3 (2001) 514-521
54. Glimelius I., Edstrom A., Fischer M., et al. Angiogenesis and mast cells in Hodgkin's lymphoma. Leukemia 19 12 (2005) 2360-2362
55. Crocker J., and Smith P.J. A quantitative study of mast cells in Hodgkin's disease. J Clin Pathol 37 5 (1984) 519-522
56. Sharma V.K., Agrawal A., Pratap V.K., et al. Mast cell reactivity in lymphoma: a preliminary communication. Indian J Cancer 29 2 (1992) 61-65
57. Levi-Schaffer F., and Piliponsky A.M. Tryptase, a novel link between allergic inflammation and fibrosis. Trends Immunol 24 4 (2003) 158-161
58. Teruya-Feldstein J., Tosato G., and Jaffe E.S. The role of chemokines in Hodgkin's disease. Leuk Lymphoma 38 3-4 (2000) 363-371
59. Teruya-Feldstein J., Jaffe E.S., Burd P.R., et al. Differential chemokine expression in tissues involved by Hodgkin's disease: direct correlation of eotaxin expression and tissue eosinophilia. Blood 93 8 (1999) 2463-2470
60. Buri C., Korner M., Scharli P., et al. CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the nonneoplastic leukocytic infiltrates of Hodgkin's disease. Blood 97 6 (2001) 1543-1548
61. Fischer M., Juremalm M., Olsson N., et al. Expression of CCL5/RANTES by Hodgkin's and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer 107 2 (2003) 197-201
62. Nilsson G., Butterfield J.H., Nilsson K., et al. Stem cell factor is a chemotactic factor for human mast cells. J Immunol 153 8 (1994) 3717-3723
63. Juremalm M., Olsson N., and Nilsson G. Selective CCL5/RANTES-induced mast cell migration through interactions with chemokine receptors CCR1 and CCR4. Biochem Biophys Res Commun 297 3 (2002) 480-485
64. Schwab U., Stein H., Gerdes J., et al. Production of a monoclonal antibody specific for Hodgkin's and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 299 5878 (1982) 65-67
65. Nawrocki J.F., Kirsten E.S., and Fisher R.I. Biochemical and structural properties of a Hodgkin's disease-related membrane protein. J Immunol 141 2 (1988) 672-680
66. Durkop H., Latza U., Hummel M., et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 68 3 (1992) 421-427
67. Gruss H.J., DaSilva N., Hu Z.B., et al. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines. Leukemia 8 12 (1994) 2083-2094
68. Josimovic-Alasevic O., Durkop H., Schwarting R., et al. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol 19 1 (1989) 157-162
69. Hansen H.P., Kisseleva T., Kobarg J., et al. A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines. Int J Cancer 63 5 (1995) 750-756
70. Gause A., Pohl C., Tschiersch A., et al. Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood 77 9 (1991) 1983-1988
71. Zanotti R., Trolese A., Ambrosetti A., et al. Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma. Ann Oncol 13 12 (2002) 1908-1914
72. Gruss H.J., Pinto A., Gloghini A., et al. CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues. Am J Pathol 149 2 (1996) 469-481
73. Wiley S.R., Goodwin R.G., and Smith C.A. Reverse signaling via CD30 ligand. J Immunol 157 8 (1996) 3635-3639
74. Maggio E., van den Berg A., Diepstra A., et al. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 13 Suppl 1) (2002) 52-56
75. Skinnider B.F., and Mak T.W. The role of cytokines in classical Hodgkin's lymphoma. Blood 99 12 (2002) 4283-4297
76. Merz H., Houssiau F.A., Orscheschek K., et al. Interleukin-9 expression in human malignant lymphomas: unique association with Hodgkin's disease and large cell anaplastic lymphoma. Blood 78 5 (1991) 1311-1317
77. Erpenbeck V.J., Hohlfeld J.M., Discher M., et al. Increased expression of interleukin-9 messenger RNA after segmental allergen challenge in allergic asthmatics. Chest 123 3 Suppl (2003) 370S
78. Knoops L., and Renauld J.C. IL-9 and its receptor: from signal transduction to tumorigenesis. Growth Factors 22 4 (2004) 207-215
79. Gruss H.J., Brach M.A., Drexler H.G., et al. Interleukin 9 is expressed by primary and cultured Hodgkin's and Reed-Sternberg cells. Cancer Res 52 4 (1992) 1026-1031
80. Aldinucci D., Poletto D., Nanni P., et al. Hodgkin's and Reed-Sternberg cells express functional c-kit receptors and interact with primary fibroblasts from Hodgkin's disease-involved lymph nodes through soluble and membrane-bound stem cell factor. Br J Haematol 118 4 (2002) 1055-1064
81. Fischer M., Bijman M., Molin D., et al. Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma. Leukemia 17 12 (2003) 2513-2516
82. Louahed J., Zhou Y., Maloy W.L., et al. Interleukin 9 promotes influx and local maturation of eosinophils. Blood 97 4 (2001) 1035-1042
83. Renauld J.C., Kermouni A., Vink A., et al. Interleukin-9 and its receptor: involvement in mast cell differentiation and T cell oncogenesis. J Leukoc Biol 57 3 (1995) 353-360
84. Matsuzawa S., Sakashita K., Kinoshita T., et al. IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. J Immunol 170 7 (2003) 3461-3467
85. Aldinucci D., Lorenzon D., Olivo K., et al. Interactions between tissue fibroblasts in lymph nodes and Hodgkin's/Reed-Sternberg cells. Leuk Lymphoma 45 9 (2004) 1731-1739
86. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 82 1 (1990) 4-6
87. Korkolopoulou P TI, Kavantzas N, Vassilakopoulos TP, et al. Angiogenesis in Hodgkin's lymphoma: a morphometric approach in 286 patients with prognostic implications. Leukemia 2005;19(6):894-900.
88. Mainou-Fowler T., Angus B., Miller S., et al. Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin's lymphoma (HL). Leuk Lymphoma 47 2 (2006) 223-230
89. Doussis-Anagnostopoulou I.A., Talks K.L., Turley H., et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin's-Reed-Sternberg cells in Hodgkin's disease. J Pathol 197 5 (2002) 677-683
90. Norrby K. Mast cells and angiogenesis. APMIS 110 5 (2002) 355-371
91. Carmeliet P. Angiogenesis in health and disease. Nat Med 9 6 (2003) 653-660
92. Gruss H.J., Herrmann F., Gattei V., et al. CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues. Leuk Lymphoma 24 5-6 (1997) 393-422
93. Hedvat C.V., Jaffe E.S., Qin J., et al. Macrophage-derived chemokine expression in classical Hodgkin's lymphoma: application of tissue microarrays. Mod Pathol 14 12 (2001) 1270-1276
94. Sanchez-Aguilera A., Montalban C., de la Cueva P., et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin's lymphoma. Blood 108 2 (2006) 662-668
95. Grulich A.E., Vajdic C.M., Kaldor J.M., et al. Birth order, atopy, and risk of non-Hodgkin's lymphoma. J Natl Cancer Inst 97 8 (2005) 587-594
96. Melbye M., Smedby K.E., Lehtinen T., et al. Atopy and risk of non-Hodgkin's lymphoma. J Natl Cancer Inst 99 2 (2007) 158-166
97. Amlot P.L., Slaney J., and Brown R. Atopy-a favourable prognostic factor for survival in Hodgkin's disease. Br J Cancer 48 2 (1983) 209-215
98. Hogan S.P., and Foster P.S. Cytokines as targets for the inhibition of eosinophilic inflammation. Pharmacol Ther 74 3 (1997) 259-283